GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B5091 RS 100329 hydrochlorideSummary: Subtype-selective α1A-adrenoceptor antagonist
- B5104 SB 200646 hydrochlorideSummary: 5-HT2C/2B receptor antagonist
- B5106 MRS 1334Summary: antagonist for the human adenosine A3 receptor
- C5043 Bufuralol (hydrochloride)Summary: non-specific β-adrenergic blocker
- C5122 (R)-SLV 319Summary: CB1 receptor antagonist
- C5649 AH 23848 (calcium salt)Summary: dual antagonist of TP1 and EP4 receptors
- C5495 DC260126Summary: free fatty acid receptor 1 (FFAR1/GPR40) antagonist
- C5373 Hexanolamino PAF C-16Summary: a PAF analog with mixed agonist/antagonist properties
- C5213 Angiotensin Fragment 1-7 (acetate)Summary: type 1 angiotensin II receptor agonist
- C5226 γ-Linolenic Acid methyl esterSummary: weak leukotriene B4 (LTB4) receptor antagonist